The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis

Kenneth A Freedberg¹, Cristina Possas², Steven Deeks³, Anna Laura Ross⁴, Katherine L Rosettie⁵, Michele Di Mascio⁶, Chris Collins⁷, Rochelle P Walensky⁸, Yazdan Yazdanpanah⁹

Affiliations

¹ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
² Oswaldo Cruz Foundation, Evandro Chagas National Institute of Infectious Diseases and Bio-Manguinhos, Rio de Janeiro, Brazil.
³ University of California San Francisco Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA; Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA; American Society for Clinical Investigation, Ann Arbor, MI, USA; Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA.
⁴ International and Scientific Relations Office, ANRS, Paris, France; International AIDS Society, Geneva, Switzerland.
⁵ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁶ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
⁷ Community Mobilization Division, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
⁸ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA.
⁹ INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, F-75018 Paris, France.

PMID: 26878073
PMCID: PMC4748959
DOI: 10.1016/S2055-6640(20)30929-8

The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis

Kenneth A Freedberg et al. J Virus Erad. 2015.

. 2015;1(4):245-249.

doi: 10.1016/S2055-6640(20)30929-8. Epub 2015 Sep 27.

Authors

Kenneth A Freedberg¹, Cristina Possas², Steven Deeks³, Anna Laura Ross⁴, Katherine L Rosettie⁵, Michele Di Mascio⁶, Chris Collins⁷, Rochelle P Walensky⁸, Yazdan Yazdanpanah⁹

Affiliations

¹ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
² Oswaldo Cruz Foundation, Evandro Chagas National Institute of Infectious Diseases and Bio-Manguinhos, Rio de Janeiro, Brazil.
³ University of California San Francisco Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA; Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA; American Society for Clinical Investigation, Ann Arbor, MI, USA; Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA.
⁴ International and Scientific Relations Office, ANRS, Paris, France; International AIDS Society, Geneva, Switzerland.
⁵ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁶ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
⁷ Community Mobilization Division, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
⁸ Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, USA; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA.
⁹ INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Services de Maladies Infectieuses et Tropicales, F-75018 Paris, France.

PMID: 26878073
PMCID: PMC4748959
DOI: 10.1016/S2055-6640(20)30929-8

Abstract

The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modeling and cost-effectiveness analysis in this agenda. We provide a brief description of the proof of concept for cure and the current directions of cure research. We then review the types of clinical economic evaluations, including cost analysis, cost-benefit analysis, and cost-effectiveness analysis. We describe the use of mathematical modeling and cost-effectiveness analysis early in the HIV epidemic as well as in the era of combination antiretroviral therapy. We then highlight the novel methodology of Value of Information analysis and its potential role in the planning of clinical trials. We close with recommendations for modeling and cost-effectiveness analysis in the HIV cure agenda.

Keywords: HIV/AIDS; cost-effectiveness; cure; mathematical modeling.

PubMed Disclaimer

References

1. UNAIDS UNAIDS report on the global AIDS epidemic. 2013. Available at: www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013... ( accessed September 2015).
1. Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817– 824. - PubMed
1. Detels R, Muñoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497– 1503. - PubMed
1. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168– 1174. - PMC - PubMed
1. Baeten JM, Donnell D, Ndase P et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399– 410. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis

Affiliations

The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis

Authors

Affiliations

Abstract

References

Grants and funding